UNSPSC 51241124: Pirnabin or pirnabine

This classification denotes an anti-glaucoma agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S3FHL03F60. European Medicines Agency schedules Pirnabin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09926MIG. Pirnabin generally arises in the molecular formula C19H24O3.

The term PIRNABIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) PIRNABIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pirnabin or pirnabine bears US NLM identifiers UMLS ID C3272437 and NCI Concept Code C95917. SMILES: O1C(C2=C(CC(CC2)C)C2C1CC(CC2OC(=O)C)C)(C)C.

UNSPSC 51241124 Pirnabin or pirnabine, a Commodity code, represents pharmaceutical active ingredients and finished-form products that state and local government facilities procure through cooperative purchasing agreements and direct supply contracts. The actual work being solicited under this code encompasses generic multi-source pharmaceuticals and over-the-counter products distributed to state agencies, local government facilities, and subordinate healthcare systems, with vendors supplying products through authorized pharmaceutical wholesalers and submitting detailed product specifications including National Drug Codes, SKUs, UPCs, dosage forms, and manufacturing locations. State and local buying is concentrated within cooperative purchasing alliances and state procurement offices; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout repeat buyer that coordinates purchasing across multiple participating states including Oregon and serves state and local government facilities statewide.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026, represents the primary recent activity under this code. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures. The contract term spans two years for new responders with optional extensions at MMCAP's sole discretion; incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Evaluations weight price competitiveness at 75 percent, with remaining points assigned to fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Products must be available in the marketplace by May 15, 2026, with contract effectiveness July 1, 2026. All products must comply with FDA requirements and possess expiration dates of at least one year from manufacture with minimum six-month shelf life. Vendors are required to maintain comprehensive insurance coverage including workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.